Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using MODS assay
| Autor: | Theodore G. Ganiats, Kathleen D. Eisenach, RL Jackson, Luz Caviedes, Timothy C. Rodwell, Jorge Coronel, Erik J. Groessl, AP Trollip, Kanchan Ajbani, S Klages, Elena Romancenco, Tommie C. Victor, Camilla Rodrigues, VP Vineet, Richard S. Garfein, David Moore, Edward Desmond, Antonino Catanzaro, Crudu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Ofloxacin
Capreomycin Moxifloxacin Drug Resistance Antitubercular Agents Sputum/microbiology Pharmacology Cardiorespiratory Medicine and Haematology MODS Amikacin/therapeutic use South Africa Kanamycin Drug Resistance Multiple Bacterial Peru Tuberculosis Multidrug-Resistant fluoroquinolones Microscopy biology Tuberculosis Multidrug-Resistant/diagnosis/drug therapy/microbiology Bacterial Drug susceptibility Pulmonary Multidrug-Resistant 3. Good health Kanamycin/therapeutic use Infectious Diseases Amikacin Tuberculosis Pulmonary/diagnosis/drug therapy/microbiology Multiple Fluoroquinolones medicine.drug Pulmonary and Respiratory Medicine drug susceptibility testing Antitubercular Agents/therapeutic use India Microbial Sensitivity Tests purl.org/pe-repo/ocde/ford#3.03.08 [https] Microbiology Article Mycobacterium tuberculosis Second line drug Predictive Value of Tests medicine Capreomycin/therapeutic use Tuberculosis Humans Tuberculosis Pulmonary aminoglycosides business.industry Breakpoint Sputum Reproducibility of Results Moldova biology.organism_classification Fluoroquinolones/therapeutic use Good Health and Well Being purl.org/pe-repo/ocde/ford#3.02.07 [https] Mycobacterium tuberculosis/drug effects/isolation & purification Microbial Sensitivity Tests/methods Ofloxacin/therapeutic use business |
| Zdroj: | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, vol 18, iss 2 Trollip, AP; Moore, D; Coronel, J; Caviedes, L; Klages, S; Victor, T; et al.(2014). Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. International Journal of Tuberculosis and Lung Disease, 18(2), 227-232. doi: 10.5588/ijtld.13.0229. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/984268pf |
| ISSN: | 1027-3719 |
| DOI: | 10.5588/ijtld.13.0229. |
| Popis: | Author(s): Trollip, AP; Moore, D; Coronel, J; Caviedes, L; Klages, S; Victor, T; Romancenco, E; Crudu, V; Ajbani, K; Vineet, VP; Rodrigues, C; Jackson, RL; Eisenach, K; Garfein, RS; Rodwell, TC; Desmond, E; Groessl, EJ; Ganiats, TG; Catanzaro, A | Abstract: ObjectiveTo establish breakpoint concentrations for the fluoroquinolones (moxifloxacin [MFX] and ofloxacin [OFX]) and injectable second-line drugs (amikacin [AMK], kanamycin [KM] and capreomycin [CPM]) using the microscopic observation drug susceptibility (MODS) assay.SettingA multinational study conducted between February 2011 and August 2012 in Peru, India, Moldova and South Africa.DesignIn the first phase, breakpoints for the fluoroquinolones and injectable second-line drugs (n = 58) were determined. In the second phase, MODS second-line drug susceptibility testing (DST) as an indirect test was compared to MGIT™ DST (n = 89). In the third (n = 30) and fourth (n = 156) phases, we determined the reproducibility and concordance of MODS second-line DST directly from sputum.ResultsBreakpoints for MFX (0.5 μg/ml), OFX (1 μg/ml), AMK (2 μg/ml), KM (5 μg/ml) and CPM (2.5 μg/ml) were determined. In all phases, MODS results were highly concordant with MGIT DST. The few discrepancies suggest that the MODS breakpoint concentrations for some drugs may be too low.ConclusionMODS second-line DST yielded comparable results to MGIT second-line DST, and is thus a promising alternative. Further studies are needed to confirm the accuracy of the drug breakpoints and the reliability of MODS second-line DST as a direct test. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|